Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG

作者：Peyman Hadji, Matty Aapro, Nasser Al-Dagri, Majed Saleh Alokail, Emmanuel Biver, Jean-Jacques Body, Maria Luisa Brandi, Janet Elizabeth Brown, Cyrille B. Confavreux, Bernard Cortet, Matthew T. Drake, Peter Robert Ebeling, Erik Fink Eriksen, Ghada El‐Hajj Fuleihan, Theresa A. Guise, Nick C. Harvey, Andreas Alois Kurth, Bente Lomholt Langdahl, Willem F. Lems, Radmila Matijević, Eugene Vincent McCloskey, Rossella Elena Nappi, Santiago Palacios, Georg Pfeiler, Jean-Yves L. Reginster, René Rizzoli, Daniele Santini, Şansın Tüzün, Catherine H. Van Poznak, Tobias De Villiers, M. Carola Zillikens, Robert Edward Coleman · 发表于：Journal of bone oncology · 年份：2025 · DOI：10.1016/j.jbo.2025.100694 · 被引用次数：22 · 研究领域：Bone health and treatments、Estrogen and related hormone effects、Bone health and osteoporosis research

Background: Women with hormone-responsive breast cancer who receive adjuvant endocrine treatment with aromatase inhibitors (AI) are known to be at higher fracture risk due to a marked increase in bone resorption. In 2017, several interdisciplinary cancer and bone societies involved in the management of women with AI-associated bone loss (AIBL) published a joint position statement comprising evidence-based recommendations and a practical management algorithm for the assessment of fracture risk and optimal treatment of this patient population. Patients and methods: In order to provide updated recommendations that reflect recent advances in the assessment and management of AIBL since publication of the 2017 joint position statement, a systematic literature review was undertaken to identify relevant studies for analysis, including systematic reviews and meta-analyses. Individual trials identified were assessed for their level of evidence based on design, size, follow-up, and evaluation of safety, as well as the impact of bone directed treatments on breast cancer outcomes. Results: New evidence was combined with the existing recommendations to provide an updated joint position statement regarding fracture risk assessment and implementation of bone-directed therapy. Conclusion: Current published literature, including recent clinical trial reports, systematic reviews and meta-analyses, continue to affirm the high risk of fractures in women with breast cancer who are receiving adjuva...